Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: A randomized, open-label, non-inferiority phase III trial

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 4173-4180

  von Au, Alexandra ^a   Milloth, Eva ^a   Diel, Ingo ^b   Stefanovic, Stefan ^a   Hennigs, Andre ^a   Wallwiener, Markus ^a   Heil, Joerg ^a   Golatta, Michael ^a   Rom, Joachim ^a   Sohn, Christof ^a   Schneeweiss, Andreas ^a   Schuetz, Florian ^a   Domschke, Christoph ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CGG Clinic Centrum für ganzheitliche Gynäkologie Mannheim   (Germany)

Author keywords

Adverse effects; Bisphosphonates; Clinical effectiveness; Metastatic bone disease

Indexed keywords

CLODRONIC ACID; PAMIDRONIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; HYPOCALCEMIA; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; OPEN STUDY; PATHOLOGIC FRACTURE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISEASE; SKIN NECROSIS; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; VOMITING;

EID: 84978485556     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S103130     Document Type: Article

References (22)

1. Robert Koch Institute. Breast cancer. 2015. Available from: http://www.krebsdaten.de/Krebs/EN/Content/Cancer_sites/Breast_cancer/breast_cancer_node.html. Accessed May 20, 2015.
2. Psaila B, Kaplan RN, Port ER, Lyden D. Priming the ‘soil’ for breast cancer metastasis: the pre-metastatic niche. Breast Dis. 2006;26:65-74.
3. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8 Suppl):1588-1594.
4. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer. 2000;36(4):476-482.
5. Weide R, Feiten S, Friesenhahn V, et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor-and Her2-positive tumors. Springer Plus. 2014;3:535.
6. Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 2000;89(2):363-368.
7. Gnant M, Balic M, Petru E, et al. Treatment of bone metastases in patients with advanced breast cancer. Breast Care (Basel). 2012;7(2):92-98.
8. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
9. Prommer EE. Toxicity of bisphosphonates. J Palliat Med. 2009;12(11):1061-1065.
10. Diel IJ. Bisphosphonates in breast cancer patients with bone metastases. Breast Care (Basel). 2010;5(5):306-311.
11. Domschke C, Schuetz F. Side effects of bone-targeted therapies in advanced breast cancer. Breast Care (Basel). 2014;9(5):332-336.
12. Hortobagyi G, Theriault R, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335(24):1785-1791.
13. Paterson A, Powles T, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59-65.
14. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014;15(1):114-122.
15. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474.
16. Eekman DA, Vis M, Bultink IE, Derikx HJ, Dijkmans BA, Lems WF. Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord. 2009;10:86.
17. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164-1172.
18. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
19. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14(9):2552-2559.
20. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998;16(12):3890-3899.
21. Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12(10):1433-1438.
22. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer. 1997;80(8 Suppl):1652-1660.